BioMed Research International

Ectonucleotidases in Cancer and Inflammation


Publishing date
05 Oct 2012
Status
Published
Submission deadline
18 May 2012

Lead Editor

1University of Montreal, Faculty of Pharmacy, Notre-Dame Hospital, 1560 Sherbrooke Street, Montreal, Quebec, Canada H2L 4M1

2Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, OK 73104-5097, USA

3Immunology Research Centre, St. Vincent's Hospital Melbourne, Fitzroy, VIC 3065, Australia


Ectonucleotidases in Cancer and Inflammation

Description

Ectonucleotidases and activation of purinergic receptors are now well recognized as a ubiquitous means of intercellular communication, regulating key physiological functions. Recent studies suggest that ectonucleotidases are involved in the pathophysiology of inflammatory diseases and cancer. Recent advances in biology have introduced new technologies to study the role of ectonucleotidases.

We invite investigators to contribute original research articles as well as review articles on the molecular and cellular pathways underlying the interactions between ectonucleotidases, cancer, and inflammation. We are particularly interested in articles describing potential therapeutic interventions aimed at modulating ectonucleotidases activity, advances in purinergic receptor signaling, new insights into the role of extracellular adenosine in cancer, and current concepts in purinergic receptor-mediated immune modulation. Potential topics include, but are not limited to:

  • Ectonucleotidases in inflammatory diseases
  • Ectonucleotidases in tumor immune escape
  • Ectonucleotidases in cancer metastasis
  • Adenosine receptor signaling and inflammation
  • Ectonucleotidases in solid cancer
  • Ectonucleotidases in leukemia/lymphomas
  • Ectonucleotidases in transplantation

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jbb/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2012
  • - Article ID 951423
  • - Editorial

Ectonucleotidases in Cancer and Inflammation

John Stagg | Linda F. Thompson | Karen M. Dwyer
  • Special Issue
  • - Volume 2012
  • - Article ID 208204
  • - Review Article

Ectonucleotidases in Solid Organ and Allogeneic Hematopoietic Cell Transplantation

Petya Chernogorova | Robert Zeiser
  • Special Issue
  • - Volume 2012
  • - Article ID 485156
  • - Review Article

CD73-Generated Adenosine: Orchestrating the Tumor-Stroma Interplay to Promote Cancer Growth

Bertrand Allard | Martin Turcotte | John Stagg
  • Special Issue
  • - Volume 2012
  • - Article ID 260983
  • - Research Article

CD73 Is Critical for the Resolution of Murine Colonic Inflammation

Margaret S. Bynoe | Adam T. Waickman | ... | Agnieszka Czopik
  • Special Issue
  • - Volume 2012
  • - Article ID 473712
  • - Research Article

Production of Adenosine by Ectonucleotidases: A Key Factor in Tumor Immunoescape

François Ghiringhelli | Mélanie Bruchard | ... | Cédric Rébé
  • Special Issue
  • - Volume 2012
  • - Article ID 959848
  • - Review Article

Ectonucleotidases in Tumor Cells and Tumor-Associated Immune Cells: An Overview

Letícia Scussel Bergamin | Elizandra Braganhol | ... | Ana Maria Oliveira Battastini
  • Special Issue
  • - Volume 2012
  • - Article ID 320495
  • - Review Article

The CD39-Adenosinergic Axis in the Pathogenesis of Immune and Nonimmune Diabetes

Joanne S. J. Chia | Jennifer L. McRae | ... | Karen M. Dwyer
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.